Cargando…

Evolution of aromatase inhibitors as an endocrine treatment for breast cancer

Detalles Bibliográficos
Autor principal:	Miller, WR
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3300238/ http://dx.doi.org/10.1186/bcr1546

Ejemplares similares

Predicting response/resistance to endocrine therapy for breast cancer
por: Miller, WR, et al.
Publicado: (2005)

Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005)

First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
por: Wong, Z-W, et al.
Publicado: (2004)

Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer
por: Colomer, R, et al.
Publicado: (2005)

Protein bomarkers Ki67, HOXC10 and HOXC11 for the prediction of response to endocrine treatment in breast cancer
por: Soon, YH, et al.
Publicado: (2015)

Microarray studies reveal novel genes associated with endocrine resistance in breast cancer
por: Burmi, RS, et al.
Publicado: (2006)

Longterm endocrine effects of cancer
por: Zacharin, Margaret
Publicado: (2013)

Characterising an aromatase inhibitor resistant breast cancer cell line
por: Harris, E, et al.
Publicado: (2012)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

Aromatase excess syndromeas a model for genomic disorder: identification of molecular bases and phenotypic determinants
por: Ogata, Tsutomu, et al.
Publicado: (2013)

Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer
por: Huifang, Li, et al.
Publicado: (2022)

Mouse models of human breast cancer: evolution or convolution?
por: Green, JE
Publicado: (2003)

Endocrine dysfunctions in patients with mitochondrial diseases
por: Cho, Ja Hyang, et al.
Publicado: (2015)

Molecular response to aromatase inhibitor treatment in primary breast cancer
por: Mackay, Alan, et al.
Publicado: (2007)

Endocrine disrupter effects on the gonads and pubertY
por: Söder, Olle
Publicado: (2013)

Stick or switch? Audit of the use of switch therapy from tamoxifen to an aromatase inhibitor in breast cancer
por: Weeraman, S, et al.
Publicado: (2010)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

Potential use of COX-2–aromatase inhibitor combinations in breast cancer
por: Bundred, N J, et al.
Publicado: (2005)

Developing new treatments for breast cancer
por: Lane, D
Publicado: (2004)

Minimising surgical treatment of early breast cancer
por: Rainsbury, R
Publicado: (2008)

Minimising oncological treatment of early breast cancer
por: Yarnold, J
Publicado: (2008)

Bisphosphonates in the adjuvant treatment of early breast cancer
por: Gnant, M
Publicado: (2009)

Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients
por: Seo, Da Hea, et al.
Publicado: (2019)

Long-term safety of aromatase inhibitors in the treatment of breast cancer
por: Nabholtz, Jean-Marc A
Publicado: (2008)

Bone loss and the aromatase inhibitors
por: Lester, J, et al.
Publicado: (2005)

Adjuvant therapy after preoperative treatment for breast cancer
por: Ciruelos, E
Publicado: (2009)

Aromatase inhibitor strategies in metastatic breast cancer
por: McArthur, Heather L, et al.
Publicado: (2010)

Clinical utilities of aromatase inhibitors in breast cancer
por: Chumsri, Saranya
Publicado: (2015)

Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2014)

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer
por: Cortés-Funes, H, et al.
Publicado: (2009)

Role of the ATM gene in radiation sensitivity, relevance to breast cancer treatment
por: Hall, J, et al.
Publicado: (2000)

Molecular heterogeneity of breast cancer: implications for treatment and clinical trial design
por: Pusztai, L
Publicado: (2009)

Translational breast cancer research in luminal breast cancer
por: Dowsett, M
Publicado: (2011)

Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
por: Leary, A, et al.
Publicado: (2006)

Use of aromatase inhibitor in a girl with peripheral precocious puberty
por: Lee, CY, et al.
Publicado: (2013)

Treatment of breast cancer with aromatase inhibitors--current status and future prospects.
por: LÃ¸nning, P. E., et al.
Publicado: (1989)

Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
por: Huang, Weiwei, et al.
Publicado: (2020)

Sweet’s Syndrome Induced by Aromatase Inhibitor in the Treatment of Early Breast Cancer
por: Cardoso, Debora, et al.
Publicado: (2020)

Signal transduction inhibitors for the treatment of rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2012)

The effects of aromatase inhibitors on lipids and thrombosis
por: Bundred, N J
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_hhrdl5j8mcunjr5sefes12llga